newsfilter
← Latest News
GlobeNewswire·

Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase